Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mary Jo Laffler

Executive Editor, US Commercial/R&D

Mary Jo oversees a talented team analyzing business and clinical activity for Scrip, Pink Sheet and In Vivo. Since starting as a reporter in 2000, Mary Jo has held editor positions across Pink Sheet and the former Pink Sheet DAILY and Pharmaceutical Approvals Monthly, and covered the drug development process from clinical trials to FDA review to approval and launch, as well as keeping track of broad industry trends and the commercial landscape. Mary Jo helped create the FDA Performance Tracker charts as a way to use regulatory data to aid development decisions and better understand agency patterns, and continues to enjoy working with data to identify industry trends through features and infographics. She frequently moderates webinars and panels at conferences. An avid reader, Mary Jo volunteers as a literacy tutor and is on the board of the local library.

Latest From Mary Jo Laffler

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Research & Development Clinical Trials

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Research & Development Clinical Trials

Bristol’s New Launches Hit Reality As New Product Portfolio Forecast Is Revised

With slower than expected sales of some newer products, Bristol lowered mid-term guidance for its new product portfolio and extended the timeline for reaching the goal to 2026. 

Sales & Earnings Business Strategies

A Momentous Day For DMD: Sarepta’s Elevidys Is First Gene Therapy Approved

The US FDA granted an accelerated approval to Sarepta’s Elevidys, the first gene therapy to be approved for some children with Duchenne muscular dystrophy.

Approvals Gene Therapy

Publisher's Spotlight: Entry Reminder For The Citeline Awards

The deadline is approaching for submissions to the 2023 Citeline Awards; gain recognition for your clinical research team, real world evidence project, diversity and inclusion efforts, and more. 

Clinical Trials Diversity & Inclusion

Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus

Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.

Deal Watch Business Strategies
See All
UsernamePublicRestriction

Register